EGFR and lung carcinoma: It is noteworthy that Shou et al. also found that progression-free survival of the group of lung cancer patients with p-STAT3 overexpression was significantly shorter (9 months vs 26 months, P < 0.05) after the application of EGFR-TKI treatment [48].